CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs
Jan 21, 2020
Momentum has been building over the last couple of months as CresoPharma (ASX:CPH) outlined its strategy for generating substantial growth in 2020.
IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy
Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer
Oct 2, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
IMC Ramps up DoD and CSIRO Partnerships in Quest to Supply Troops
Jul 17, 2018
Immuron Limited (ASX:IMC | NASDAQ:IMRN) has provided a steady stream of positive news across its microbiome immunotherapy platform — which includes assets that are preclinical, at clinical stage, and the already on-the-market Travelan® product.
MXC Moves Towards Commercial-Scale Pot Production with GMP Manufacturing Licence
Jul 13, 2018
Nimble ASX pot-stock MGC Pharmaceuticals (ASX:MXC) this week smashed a pivotal milestone, scoring full manufacturing licence for its world-class European compounding and manufacturing facility for the production of euGMP grade medicinal cannabis products.
Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism
Jul 10, 2018
Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.
Revolutionary MedTech Device: a New Frontier in Autism Treatment
Jun 26, 2018
Today’s company has created the first and only regulated medical device for the management of autism in a home setting.
IMC Reports Rising Revenues & Eyes Colitis Market
Jun 7, 2018
Immuron Limited (ASX:IMC | NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.